Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529112 | 0.84 | ALDH1A1 (0.39) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL17478833 | 0.80 | MCL1 (0.42) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL5552743 | 0.79 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1HPGDLCK | |
| SCHEMBL10572753 | 0.76 | ALDH1A1 (0.44) | KDM4EHSD17B10ALDH1A1HPGDLCK | |
| SCHEMBL3514549 | 0.76 | CA12 (0.42) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL4701685 | 0.74 | CA12 (0.45) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL7813776 | 0.72 | MGAM (0.44) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| Sulfosalicylic SCHEMBL28230054 | 0.72 | ALDH1A1 (0.93) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL3982338 | 0.71 | KDM4E (0.37) | KDM4EHSD17B10ALDH1A1HPGDKMT2A | |
| SCHEMBL429271 | 0.71 | AKR1C3 (0.48) | KDM4EHSD17B10ALDH1A1HPGDCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005693-A | Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis | 河南中医药大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122005693-A | Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis | 河南中医药大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| US-7067660-B2 | such as 1-(4-ethoxy-3-formylphenylsulfonyl)-4-methylpiperazine; for use as anti-impotence agent | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-7005520-B2 | Process for the preparation of pyrazolopyrimidinones | PFIZER INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| EP-1305314-B1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1092720-B1 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PFIZER INC. | 2002-04-04 | — | — | US | disclosed |
| US-6350751-B1 | ANHYDROUS PARA-TOLUENESULPHONIC ACID SALTS OF 3-ETHYL-5-(5-(4-ETHYL PIPERAZIN-1-YLSULPHONYL)-2-(2-METHOXYETHOXY) PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)METHYL-2,6-DIHYDRO-7H-PYRAZOLO | PFIZER INC. | 2002-02-26 | — | — | US | disclosed |
| WO-2002010171-A1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LIMITED (GB) | 2002-02-07 | — | — | WO | disclosed |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001098284-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001098303-A1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001027101-A2 | ANHYDROUS SALT | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | KDM4E 1687/4885HSD17B10 1157/4885ALDH1A1 720/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | KDM4E 1883/4885HSD17B10 1144/4885ALDH1A1 758/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | KDM4E 1883/4885HSD17B10 1144/4885ALDH1A1 758/4885 |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | KDM4E 3008/4885HSD17B10 458/4885ALDH1A1 163/4885 |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | KDM4E 2782/4885HSD17B10 2469/4885ALDH1A1 812/4885 |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PDE3A, PDE5A, PDE3B | KDM4E 1340/4885HSD17B10 1179/4885ALDH1A1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.